Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.nektar.com
Nektar Therapeutics News Releases
Get the latest updates from Nektar Therapeutics News Releases directly as they happen.
Follow now 71 followers
Latest posts
Last updated 1 day ago
Nektar Therapeutics Reports First Quarter 2025 Financial Results
1 day ago
SAN FRANCISCO , May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
8 days ago
SAN FRANCISCO , May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
about 2 months ago
SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
about 2 months ago
SAN FRANCISCO , March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
2 months ago
SAN FRANCISCO , March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
2 months ago
SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
2 months ago
SAN FRANCISCO , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
2 months ago
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study --...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
3 months ago
SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
4 months ago
SAN FRANCISCO , Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)...
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
5 months ago
73% of the NKTR-255 treatment group compared to 50% of the placebo...
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
6 months ago
- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models...